menu
    • menu
    [{"orgOrder":0,"company":"Pharmaron","sponsor":"Immuron","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Bovine Colostrum","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pharmaron","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pharmaron \/ Pharmaron","highestDevelopmentStatusID":"12","companyTruncated":"Pharmaron \/ Pharmaron"},{"orgOrder":0,"company":"Pharmaron","sponsor":"OliX Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Agreement","leadProduct":"OLX703A","moa":"HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Pharmaron","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmaron \/ OliX Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Pharmaron \/ OliX Pharmaceutical"}]

    Find Clinical Drug Pipeline Developments & Deals by Pharmaron

    Menu

    Pharmaron

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Pharmaron

    U.S.A arrow
    ICHH-25
    Not Confirmed

    Pharmaron

    U.S.A arrow
    ICHH-25
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Bovine Colostrum

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : IND Enabling

    Recipient : Immuron

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Immuron Executes Travelan Clinical Trial Agreement with US-based Pharmaron

    Details : The Phase II clinical trial will evaluate the efficacy of a single dose regimen of Travelan® in a controlled human infection model (CHIM) using the enterotoxigenic Escherichia coli (ETEC) strain H10407.

    Product Name : Travelan

    Product Type : Large molecule

    Upfront Cash : Undisclosed

    October 04, 2022

    Lead Product(s) : Bovine Colostrum

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : IND Enabling

    Recipient : Immuron

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Pharmaron

    U.S.A arrow
    ICHH-25
    Not Confirmed

    Pharmaron

    U.S.A arrow
    ICHH-25
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : OLX703A

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Preclinical

    Sponsor : OliX Pharmaceutical

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    OliX Pharmaceuticals Enters Agreement with Pharmaron to Advance Non-clinical Toxicology Testing for Hepatitis ...

    Details : OLX703A utilizes GalNAc-asiRNA technology and is designed to inhibit all HBV transcripts and proteins, including hepatitis B surface antigen (HBsAg).

    Product Name : OLX703A

    Product Type : Oligonucleotide

    Upfront Cash : Undisclosed

    October 20, 2021

    Lead Product(s) : OLX703A

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Preclinical

    Sponsor : OliX Pharmaceutical

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth